Clinical trials: Alopecia Universalis
Alopecia Areata
Treatment of Alopecia Areata (AA) With Dupilumab in Patients With and Without Atopic Dermatitis (AD)
Alopecia areata is a medical condition, in which the hair falls out in patches. The hair can fall out on the scalp or elsewhere on the face and body.
- Trial name
- NCT03359356
- Testing
- Dupilumab
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Alopecia Areata, Alopecia Totalis
Phase 2 Trial of BNZ-1 in Patients With Moderate to Severe Alopecia Areata
This study is a randomized, double-blind, placebo-controlled, multi-center, dose-ranging study to characterize the efficacy and safety of BNZ-1 administered by slow IV push weekly for 3 months to adults diagnosed with moderate to…
- Conditions
- Alopecia Areata, Alopecia Totalis, Alopecia Universalis
- Trial name
- NCT03532958
- Testing
- BNZ-1, Normal saline
- Sponsor
- Equillium
Alopecia Areata, Alopecia Totalis
Efficacy of Oral Tofacitinib in Moderate to Severe Alopecia Areata, Totalis and Universalis at Tertiary Care Hospital, Karachi.
To determine the efficacy of oral Tofacitinib in the treatment of moderate to severe alopecia areata, totalis and universalis at tertiary care hospital of Karachi, Pakistan.
- Conditions
- Alopecia Areata, Alopecia Totalis, Alopecia Universalis
- Trial name
- NCT06278402
- Testing
- Tofacitinib
- Where
- Pakistan
- Volunteers
- 30 people
- Sponsor
- Jinnah Hospital
Alopecia Areata(AA), Alopecia Areata (AA)
Cyclosporine Or Methotrexate for Pediatric Alopecia Areata: Routine Clinical Care Effectiveness Study
Rationale: Since the introduction of Janus kinase (JAK) inhibitors, there has been a significant advancement in the treatment of pediatric alopecia areata.
- Conditions
- Alopecia Areata(AA), Alopecia Areata (AA), Alopecia Totalis/Universalis, Alopecia Universalis (AU)
- Trial name
- COMPARE (NCT07381556)
- Testing
- Methotrexate, Cyclosporin (CSA)
- Where
- Netherlands
- Volunteers
- 50 people
- Sponsor
- Erasmus Medical Center
Alopecia Totalis/Universalis
Abatacept Costimulatory Blockade in the Treatment of Alopecia Totalis/Universalis
Will Abatacept reduce priming of the hair follicle specific T cells and thereby reduce hair follicle associated infiltration and improve hair growth.
- Trial name
- NCT01314495
- Testing
- Abatacept, Inactive infusion
- Sponsor
- Julian M. Mackay-Wiggan
Alopecia Areata, Alopecia Totalis
Clinical Application of Stem Cell Educator Therapy in Alopecia Areata
Alopecia areata (AA) is a common autoimmune disease that results in loss of body hair in varying degrees. The condition is estimated to affect more than 6.8 million people in the United States alone (naaf.org), with a worldwide…
- Conditions
- Alopecia Areata, Alopecia Totalis, Alopecia Universalis
- Trial name
- NCT04011748
- Testing
- Stem Cell Educator therapy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Throne Biotechnologies Inc.
Alopecia Areata
PF-06651600 for the Treatment of Alopecia Areata
This is a global Phase 2b/3 study to evaluate the safety and effectiveness of an investigational study drug (called PF-06651600) in adults and adolescents (12 years and older) who have 50% or greater scalp hair loss.
- Trial name
- ALLEGRO-2b/3 (NCT03732807)
- Testing
- PF-06651600 Induction Dose, PF-06651600 Maintenance Dose #1, PF-06651600 Maintenance Dose #2
- Where
- 155 sites in United States, Argentina and 16 more
- Volunteers
- 718 people
- Sponsor
- Pfizer
Alopecia Areata
Pre-approval Single-patient Expanded Access for Ritlecitinib (PF-06651600)
Provide pre-approval single patient Expanded Access (compassionate use) of Ritlecitinib for patients.
- Trial name
- NCT05522556
- Testing
- Ritlecitinib
- Sponsor
- Pfizer
Alopecia Areata
Study To Evaluate The Efficacy Of Tofacitinib In Moderate To Severe Alopecia Areata, Totalis And Universalis
This is an open-label pilot study of tofacitinib taken daily for 6 months in the treatment of moderate to severe AA, and alopecia totalis or universalis, followed by 6 months follow-up off drug to assess the incidence and timing…
- Trial name
- NCT02299297
- Testing
- Tofacitinib
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Columbia University
Alopecia Areata, Alopecia Totalis
Systemic Treatments for Alopecia Areata Registry
A multicenter prospective registry (STA2R) is conducted to assess systemic treatments for alopecia areata, focusing on effectiveness, safety, and long-term outcomes.
- Conditions
- Alopecia Areata, Alopecia Totalis, Alopecia Universalis, Hair Loss
- Trial name
- STA2R (NCT06283316)
- Where
- Netherlands
- Volunteers
- 10,000 people
- Sponsor
- Erasmus Medical Center
Alopecia Areata, Alopecia Totalis (AT)
Tofacitinib vs Methotrexate for Severe Alopecia Areata (TOFA-MTX-AA)
This study will compare two oral medicines-tofacitinib and methotrexate-for treating severe alopecia areata, including alopecia totalis (loss of all scalp hair) and alopecia universalis (loss of scalp and body hair).
- Conditions
- Alopecia Areata, Alopecia Totalis (AT), Alopecia Universalis
- Trial name
- TOFA-MTX-AA (NCT07406204)
- Testing
- Tofacitinib, Methotrexate
- Volunteers
- 78 people
- Sponsor
- Hayat Abad Medical Complex, Peshawar
Alopecia Areata, Alopecia Totalis
Topical Tofacitinib for the Treatment of Alopecia Areata and Its Variants
The purpose of the study is to investigate the use of topical tofacitinib to promote hair regrowth in patients with alopecia areata, alopecia totalis, and alopecia universalis.
- Conditions
- Alopecia Areata, Alopecia Totalis, Alopecia Universalis
- Trial name
- NCT02812342
- Testing
- Tofacitinib ointment
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Yale University
Alopecia Areata, Alopecia Totalis
Open Label Study of ATI-50002 Topical Solution Administered to Adult Subjects With Eyebrow Loss Due to Alopecia Areata
The main objective of this study is to assess the safety, tolerability and efficacy of ATI-50002 Topical Solution in subjects with unilateral or bilateral loss of eyebrow hair due to alopecia areata (AA), alopecia universalis…
- Conditions
- Alopecia Areata, Alopecia Totalis, Alopecia Universalis
- Trial name
- NCT03551821
- Testing
- ATI-50002
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Aclaris Therapeutics, Inc.
Alopecia Areata
PLACEBO-CONTROLLED SAFETY STUDY OF RITLECITINIB (PF-06651600) IN ADULTS WITH ALOPECIA AREATA
This is a global Phase 2a randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of ritlecitinib in adults aged 18 to ≤50 years of age with ≥25% scalp hair loss due to Alopecia Areata (AA).
- Trial name
- Allegro2a (NCT04517864)
- Testing
- PF-06651600
- Where
- 38 sites in United States, Australia and 2 more
- Volunteers
- 71 people
- Sponsor
- Pfizer
Alopecia Areata
A Pilot Study of Tralokinumab in Subjects With Moderate to Severe Alopecia Areata
The purpose of this study is to assess whether tralokinumab can be a helpful treatment for alopecia areata. This is a randomized, double-blind, placebo-controlled pilot study of a total of 30 subjects with moderate to severe…
- Trial name
- NCT02684097
- Testing
- Tralokinumab
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Emma Guttman